126 related articles for article (PubMed ID: 27905037)
1. Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.
Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM
Bull Exp Biol Med; 2016 Dec; 162(2):240-243. PubMed ID: 27905037
[TBL] [Abstract][Full Text] [Related]
2. Role of JAK1, JAK2, and JAK3 in Functional Stimulation of Mesenchymal Precursor Cells by Alkaloid Songorine.
Zyuz'kov GN; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Stavrova LA; Udut VV; Minakova MY; Dygai AM; Chaikovskii AV; Agafonov VI; Zhdanov VV
Bull Exp Biol Med; 2017 Aug; 163(4):443-446. PubMed ID: 28853089
[TBL] [Abstract][Full Text] [Related]
3. Implication of JAK1, JAK2, and JAK3 in the Realization of Proliferation and Differentiation Potential of Mesenchymal Progenitor Cells In Vitro.
Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Simanina EV; Polyakova TY; Chaikovskii AV; Stavrova LA; Udut VV; Agafonov VI; Burmina YV; Danilets MG; Minakova MY; Dygai AM
Bull Exp Biol Med; 2016 Jun; 161(2):224-7. PubMed ID: 27383175
[TBL] [Abstract][Full Text] [Related]
4. Particular Role of JAK/STAT3 Signaling in Functional Control of Mesenchymal Progenitor Cells.
Zyuz'kov GN; Udut EV; Miroshnichenko LA; Polyakova TY; Simanina EV; Stavrova LA; Chaikovskii AV; Agafonov VI; Borodulina EV; Timofeev MS; Zyuz'kova YN; Danilets MG; Zhdanov VV; Udut VV
Bull Exp Biol Med; 2018 Jan; 164(3):316-319. PubMed ID: 29308566
[TBL] [Abstract][Full Text] [Related]
5. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
6. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
7. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
8. PI3K, MAPK EPK1/2 and p38 are involved in the realization of growth potential of mesenchymal progenitor cells under the influence of basic fibroblast growth factor.
Zyuz'kov GN; Danilets MG; Ligacheva AA; Zhdanov VV; Udut EV; Miroshnichenko LA; Simanina EV; Chaikovskii AV; Trofimova ES; Minakova MY; Udut VV; Dygai AM
Bull Exp Biol Med; 2014 Aug; 157(4):436-9. PubMed ID: 25113604
[TBL] [Abstract][Full Text] [Related]
9. JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.
Yan J; Zhang Z; Yang J; Mitch WE; Wang Y
J Am Soc Nephrol; 2015 Dec; 26(12):3060-71. PubMed ID: 26032813
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
11. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
Oh K; Joo KM; Jung YS; Lee J; Kang H; Lee HY; Lee DS
J Immunol Methods; 2010 Mar; 354(1-2):45-52. PubMed ID: 20138049
[TBL] [Abstract][Full Text] [Related]
12. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
13. Role of JAK/STAT3 Signaling in Functional Stimulation of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.
Zyuz'kov GN; Udut EV; Miroshnichenko LA; Polyakova TY; Simanina EV; Stavrova LA; Prosekin GA; Minakova MY; Borodulina EV; Mareev IV; Gurto RV; Zhdanov VV; Udut VV
Bull Exp Biol Med; 2018 May; 165(1):18-21. PubMed ID: 29797128
[TBL] [Abstract][Full Text] [Related]
14. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
18. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
19. Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor.
Field SD; Arkin J; Li J; Jones LH
ACS Chem Biol; 2017 May; 12(5):1183-1187. PubMed ID: 28318222
[TBL] [Abstract][Full Text] [Related]
20. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
